Evosep receives strategic investment from Novo Holding A/S to accelerate its effort on clinical proteomics
Evosep today announced that Novo Holdings A/S has become a minority shareholder in Evosep Aps with a US$ 40m investment to further Evosep’s technology and application portfolio for clinical proteomics.
Source: news-medical.net